# Rambus Inc: financial statements, quarterly

RMBS · Nasdaq · CIK 917273 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rmbs.md) · [Financials](/companies/rmbs/financials.md) · [Filings](/companies/rmbs/filings.md) · [Insiders](/companies/rmbs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rmbs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [122 d](/filings/0001193125-26-057101.md) | [118](/filings/0000917273-25-000075.md) | [132](/filings/0000950170-25-099621.md) | [146](/filings/0001193125-25-253472.md) | [161 d](/filings/0001193125-26-057101.md) | [167](/filings/0001193125-26-186931.md) | [172](/filings/0001193125-26-321000.md) | [179](/filings/0001193125-26-431941.md) | [190 d](/filings/0001193125-26-057101.md) | [180](/filings/0001193125-26-186931.md) | [207](/filings/0001193125-26-321000.md) | [218](/filings/0001193125-26-431941.md) |
| Cost of revenue | $m | [24.1 d](/filings/0001193125-26-057101.md) | [23.7](/filings/0000917273-25-000075.md) | [26.8](/filings/0000950170-25-099621.md) | [28.1](/filings/0001193125-25-253472.md) | [31.5 d](/filings/0001193125-26-057101.md) | [32.8](/filings/0001193125-26-186931.md) | [34.8](/filings/0001193125-26-321000.md) | [36.6](/filings/0001193125-26-431941.md) | [40.2 d](/filings/0001193125-26-057101.md) | [36.5](/filings/0001193125-26-186931.md) | [42.0](/filings/0001193125-26-321000.md) | [47.4](/filings/0001193125-26-431941.md) |
| Gross profit | $m | [98.1 d](/filings/0001193125-26-057101.md) | [94.2](/filings/0000917273-25-000075.md) | [105](/filings/0000950170-25-099621.md) | [117](/filings/0001193125-25-253472.md) | [130 d](/filings/0001193125-26-057101.md) | [134](/filings/0001193125-26-186931.md) | [137](/filings/0001193125-26-321000.md) | [142](/filings/0001193125-26-431941.md) | [150 d](/filings/0001193125-26-057101.md) | [144](/filings/0001193125-26-186931.md) | [165](/filings/0001193125-26-321000.md) | [171](/filings/0001193125-26-431941.md) |
| Research and development | $m | [36.0 d](/filings/0001193125-26-057101.md) | [37.4](/filings/0000917273-25-000075.md) | [40.5](/filings/0000950170-25-099621.md) | [41.3](/filings/0001193125-25-253472.md) | [43.7 d](/filings/0001193125-26-057101.md) | [42.6](/filings/0001193125-26-186931.md) | [46.3](/filings/0001193125-26-321000.md) | [49.5](/filings/0001193125-26-431941.md) | [49.2 d](/filings/0001193125-26-057101.md) | [50.2](/filings/0001193125-26-186931.md) | [51.1](/filings/0001193125-26-321000.md) | [49.4](/filings/0001193125-26-431941.md) |
| Selling, general and administrative | $m | [25.7 d](/filings/0001193125-26-057101.md) | [25.8](/filings/0000917273-25-000075.md) | [24.4](/filings/0000950170-25-099621.md) | [25.9](/filings/0001193125-25-253472.md) | [28.0 d](/filings/0001193125-26-057101.md) | [28.1](/filings/0001193125-26-186931.md) | [28.1](/filings/0001193125-26-321000.md) | [29.2](/filings/0001193125-26-431941.md) | [30.0 d](/filings/0001193125-26-057101.md) | [31.7](/filings/0001193125-26-186931.md) | [38.3](/filings/0001193125-26-321000.md) | [37.7](/filings/0001193125-26-431941.md) |
| Operating income | $m | [35.1 d](/filings/0001193125-26-057101.md) | [30.1](/filings/0000917273-25-000075.md) | [40.3](/filings/0000950170-25-099621.md) | [54.7](/filings/0001193125-25-253472.md) | [57.9 d](/filings/0001193125-26-057101.md) | [63.1](/filings/0001193125-26-186931.md) | [63.0](/filings/0001193125-26-321000.md) | [63.3](/filings/0001193125-26-431941.md) | [70.8 d](/filings/0001193125-26-057101.md) | [61.8](/filings/0001193125-26-186931.md) | [72.7](/filings/0001193125-26-321000.md) | [83.7](/filings/0001193125-26-431941.md) |
| Interest expense | $m | [0.4 d](/filings/0000917273-24-000028.md) | [0.4](/filings/0000917273-24-000088.md) | [0.4](/filings/0000950170-25-099621.md) | [0.3](/filings/0001193125-25-253472.md) | [0.4 d](/filings/0001193125-26-057101.md) | [0.4](/filings/0001193125-26-186931.md) | [0.4](/filings/0001193125-26-321000.md) | [0.3](/filings/0001193125-26-431941.md) | [0.3 d](/filings/0001193125-26-057101.md) | [0.3](/filings/0001193125-26-186931.md) | [0.3](/filings/0001193125-26-321000.md) | [0.3](/filings/0001193125-26-431941.md) |
| Income tax | $m | [4.3 d](/filings/0001193125-26-057101.md) | [1.5](/filings/0000917273-25-000075.md) | [8.3](/filings/0000950170-25-099621.md) | [10.4](/filings/0001193125-25-253472.md) | [0.1 d](/filings/0001193125-26-057101.md) | [7.3](/filings/0001193125-26-186931.md) | [9.9](/filings/0001193125-26-321000.md) | [20.9](/filings/0001193125-26-431941.md) | [13.4 d](/filings/0001193125-26-057101.md) | [8.8](/filings/0001193125-26-186931.md) | [11.9](/filings/0001193125-26-321000.md) | [16.0](/filings/0001193125-26-431941.md) |
| Net income | $m | [58.5 d](/filings/0001193125-26-057101.md) | [32.9](/filings/0000917273-25-000075.md) | [36.1](/filings/0000950170-25-099621.md) | [48.7](/filings/0001193125-25-253472.md) | [62.2 d](/filings/0001193125-26-057101.md) | [60.3](/filings/0001193125-26-186931.md) | [57.9](/filings/0001193125-26-321000.md) | [48.4](/filings/0001193125-26-431941.md) | [63.8 d](/filings/0001193125-26-057101.md) | [59.9](/filings/0001193125-26-186931.md) | [67.6](/filings/0001193125-26-321000.md) | [74.6](/filings/0001193125-26-431941.md) |
| Diluted EPS | $ per share | not reported | [0.30](/filings/0000917273-25-000075.md) | [0.33](/filings/0000950170-25-099621.md) | [0.45](/filings/0001193125-25-253472.md) | not reported | [0.56](/filings/0001193125-26-186931.md) | [0.53](/filings/0001193125-26-321000.md) | [0.44](/filings/0001193125-26-431941.md) | not reported | [0.55](/filings/0001193125-26-186931.md) | [0.61](/filings/0001193125-26-321000.md) | [0.69](/filings/0001193125-26-431941.md) |
| Basic EPS | $ per share | not reported | [0.30](/filings/0000917273-25-000075.md) | [0.33](/filings/0000950170-25-099621.md) | [0.45](/filings/0001193125-25-253472.md) | not reported | [0.56](/filings/0001193125-26-186931.md) | [0.54](/filings/0001193125-26-321000.md) | [0.45](/filings/0001193125-26-431941.md) | not reported | [0.55](/filings/0001193125-26-186931.md) | [0.62](/filings/0001193125-26-321000.md) | [0.69](/filings/0001193125-26-431941.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [94.8](/filings/0000917273-25-000021.md) | [113](/filings/0000917273-24-000088.md) | [125](/filings/0000917273-24-000100.md) | [114](/filings/0000917273-24-000107.md) | [99.8](/filings/0001193125-26-057101.md) | [132](/filings/0000917273-25-000075.md) | [87.8](/filings/0000950170-25-099621.md) | [79.2](/filings/0001193125-25-253472.md) | [183](/filings/0001193125-26-431941.md) | [134](/filings/0001193125-26-186931.md) | [87.7](/filings/0001193125-26-321000.md) | [111](/filings/0001193125-26-431941.md) |
| Current assets | $m | [631](/filings/0000917273-25-000021.md) | [576](/filings/0000917273-24-000088.md) | [610](/filings/0000917273-24-000100.md) | [612](/filings/0000917273-24-000107.md) | [690](/filings/0001193125-26-057101.md) | [719](/filings/0000917273-25-000075.md) | [784](/filings/0000950170-25-099621.md) | [869](/filings/0001193125-25-253472.md) | [989](/filings/0001193125-26-431941.md) | [1,000](/filings/0001193125-26-186931.md) | [1,087](/filings/0001193125-26-321000.md) | [1,051](/filings/0001193125-26-431941.md) |
| Total assets | $m | [1,258](/filings/0000917273-25-000021.md) | [1,209](/filings/0000917273-24-000088.md) | [1,251](/filings/0000917273-24-000100.md) | [1,252](/filings/0000917273-24-000107.md) | [1,343](/filings/0001193125-26-057101.md) | [1,379](/filings/0000917273-25-000075.md) | [1,468](/filings/0000950170-25-099621.md) | [1,406](/filings/0001193125-25-253472.md) | [1,530](/filings/0001193125-26-431941.md) | [1,533](/filings/0001193125-26-186931.md) | [1,612](/filings/0001193125-26-321000.md) | [1,558](/filings/0001193125-26-431941.md) |
| Current liabilities | $m | [89.1](/filings/0000917273-25-000021.md) | [82.6](/filings/0000917273-24-000088.md) | [85.0](/filings/0000917273-24-000100.md) | [74.1](/filings/0000917273-24-000107.md) | [81.8](/filings/0001193125-26-057101.md) | [70.9](/filings/0000917273-25-000075.md) | [72.2](/filings/0000950170-25-099621.md) | [74.8](/filings/0001193125-25-253472.md) | [121](/filings/0001193125-26-431941.md) | [102](/filings/0001193125-26-186931.md) | [111](/filings/0001193125-26-321000.md) | [112](/filings/0001193125-26-431941.md) |
| Total liabilities | $m | [220](/filings/0000917273-25-000021.md) | [217](/filings/0000917273-24-000088.md) | [222](/filings/0000917273-24-000100.md) | [213](/filings/0000917273-24-000107.md) | [222](/filings/0001193125-26-057101.md) | [220](/filings/0000917273-25-000075.md) | [240](/filings/0000950170-25-099621.md) | [118](/filings/0001193125-25-253472.md) | [165](/filings/0001193125-26-431941.md) | [140](/filings/0001193125-26-186931.md) | [146](/filings/0001193125-26-321000.md) | [141](/filings/0001193125-26-431941.md) |
| Shareholders' equity | $m | [1,038](/filings/0001193125-26-057101.md) | [992](/filings/0000950170-25-099621.md) | [1,029](/filings/0001193125-25-253472.md) | [1,039](/filings/0001193125-25-253472.md) | [1,121](/filings/0001193125-26-431941.md) | [1,160](/filings/0001193125-26-321000.md) | [1,228](/filings/0001193125-26-431941.md) | [1,288](/filings/0001193125-26-431941.md) | [1,364](/filings/0001193125-26-431941.md) | [1,393](/filings/0001193125-26-321000.md) | [1,467](/filings/0001193125-26-431941.md) | [1,418](/filings/0001193125-26-431941.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [54.9 d](/filings/0001193125-26-057101.md) | [39.1](/filings/0000917273-25-000075.md) | [70.4 d](/filings/0000950170-25-099621.md) | [62.1 d](/filings/0001193125-25-253472.md) | [59.0 d](/filings/0001193125-26-057101.md) | [77.4](/filings/0001193125-26-186931.md) | [94.4 d](/filings/0001193125-26-321000.md) | [88.4 d](/filings/0001193125-26-431941.md) | [99.8 d](/filings/0001193125-26-057101.md) | [83.2](/filings/0001193125-26-186931.md) | [61.2 d](/filings/0001193125-26-321000.md) | [102 d](/filings/0001193125-26-431941.md) |
| Capital expenditure | $m | [0.8 d](/filings/0001193125-26-057101.md) | [3.0](/filings/0000917273-25-000075.md) | [11.3 d](/filings/0000950170-25-099621.md) | [9.9 d](/filings/0001193125-25-253472.md) | [6.5 d](/filings/0001193125-26-057101.md) | [7.9](/filings/0001193125-26-186931.md) | [6.5 d](/filings/0001193125-26-321000.md) | [5.9 d](/filings/0001193125-26-431941.md) | [6.5 d](/filings/0001193125-26-057101.md) | [11.6](/filings/0001193125-26-186931.md) | [9.1 d](/filings/0001193125-26-321000.md) | [6.6 d](/filings/0001193125-26-431941.md) |
| Share repurchases | $m | [0.2 d](/filings/0001193125-26-057101.md) | [50.8](/filings/0000917273-25-000075.md) | [12.5 d](/filings/0000950170-25-099621.md) | [50.0 d](/filings/0001193125-25-253472.md) | [0.0 d](/filings/0001193125-26-057101.md) | [2.2](/filings/0001193125-26-186931.md) | [3.7 d](/filings/0001193125-26-321000.md) | [0.0 d](/filings/0001193125-26-431941.md) | [1.3 d](/filings/0001193125-26-057101.md) | [2.6](/filings/0001193125-26-186931.md) | [0.4 d](/filings/0001193125-26-321000.md) | [135 d](/filings/0001193125-26-431941.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [111](/filings/0000917273-24-000088.md) | [112](/filings/0000917273-24-000100.md) | [111](/filings/0000917273-24-000107.md) | [110](/filings/0000917273-25-000075.md) | [109](/filings/0000950170-25-099621.md) | [108](/filings/0001193125-25-253472.md) | [109](/filings/0001193125-26-186931.md) | [109](/filings/0001193125-26-321000.md) | [109](/filings/0001193125-26-431941.md) | [110](/filings/0001193125-26-186931.md) | [110](/filings/0001193125-26-321000.md) | [109](/filings/0001193125-26-431941.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 107,095,985 at 2026-09-30, from the cover of the [10-Q filed 2026-10-26](/filings/0001193125-26-431941.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 26, 2026, 16:30 ET. No prices; not investment advice.